Percutaneous left atrial appendage occlusion: putting the most lethal human attachment behind bars by Caixeta, Adriano et al.
Editorial
Percutaneous Left Atrial Appendage Occlusion: Putting the Most 
Lethal Human Attachment Behind Bars
Adriano Caixeta1,2, Erlon O. de Abreu Silva2,  Philippe Généreux3
Hospital Israelita Albert Einstein1, São Paulo, SP; Escola Paulista de Medicina, Universidade Federal de São Paulo2, São Paulo, SP - Brazil; 
Columbia University Medical Center and the Cardiovascular Research Foundation3,  New York, NY - USA
Mailing Address Adriano Caixeta •
Av. Dom Armando Lombardi, 819, Apto. 21B, Vila Progredior. Postal Code 
05616-011, Sao Paulo, SP – Brazil
E-mail: adriano.caixeta@einstein.br
Manuscript received October 18, 2012; manuscript revised October 18, 
2012; accepted October 18, 2012.
Keywords
Atrial Appendage / physiopathology; Atrial Fibrillation 
/ complications; Anticoagulants / therapeutic use; Heart 
Catheterization.
Atrial fibrillation (AF) is the most common sustained 
cardiac arrhythmia, affecting millions of people worldwide. 
Since AF mainly affects the elderly, its prevalence is 
expected to increase with the aging of the population. In 
the United States alone, over 15 million people will have 
AF by the year 20501. Among its many consequences, 
the one that carries the greatest burden with regard to 
morbidity is embolic stroke. The rate of ischemic stroke 
among patients with nonvalvular AF averages 5% per year, 
a fivefold increase compared with that of people without 
AF2. The risk of stroke increases with age. The annual risk 
of stroke attributed to AF is 1.5% in subjects aged 50 to 59 
years and 23% in those aged 80 to 89 years. Importantly, the 
left atrial appendage (LAA) is the primary site of thrombus 
formation as a precursor to embolic stroke in nonvalvular 
AF patients1. In these patients, anticoagulation with warfarin 
has become standard medical therapy, reducing the risk of 
stroke by ~60%. Nonetheless, the long-term use of warfarin 
carries several drawbacks and complications, including 
non-tolerance, non-adherence, interactions with food and 
other medications, a very narrow therapeutic range, and an 
increased risk of bleeding3. In addition, oral anticoagulation 
is contraindicated in up to 40% of patients with AF who 
are at risk for stroke. Accordingly, several surgical and 
percutaneous techniques have been explored to occlude 
the LAA for stroke prevention. As an alternative to surgical 
closure, percutaneous transcatheter LAA closure (LAAC) 
represents a novel approach to prevent strokes in high-
risk patients with nonvalvular AF and contraindications to 
long-term oral anticoagulant therapy. In selected patients, 
dedicated LAAC devices such as Watchman (Atritech Inc, 
Plymouth, Minn) and the Amplatzer cardiac plug (ACP; 
AGA Medical Corp., Minneapolis, MN, USA) have shown 
encouraging initial results. For instance, The Watchman 
Left Atrial Appendage System for Embolic Protection in 
Patients With AF (PROTECT AF) trial — the only randomized 
study to address this issue — has shown the therapeutic 
noninferiority of LAAC when used as an alternative to long-
term warfarin in preventing stroke (with less intracranial 
hemorrhages) in patients with a CHADS2 score ≥1
4. The 
events in the Watchman group occurred early and were 
related to the procedure, predominantly pericardial effusion 
and procedural stroke related to air embolism. 
Besides the aforementioned clinical criteria for 
percutaneous LAAC and the assessment of stroke risk 
by CHADS2 and the CHA2DS2-VASc scores, anatomical 
characteristics of the LAA should be taken into account 
when selecting candidates for this procedure. The left atrial 
appendage is a long, tubular and hooked structure which has 
a narrow junction with the venous component of the atrium. 
In adults, the mean volume of the LAA is approximately 5.2 
ml, with orifice diameters ranging from 5 to 40 mm. There 
is considerable inter-individual variability in the size and 
shape of the LAA. Functions of the LAA include modulation 
of sympathetic and parasympathetic tone, decompression 
of the left atrium in the setting of elevated atrial pressure 
and volume overload, production of natriuretic peptides 
(atrial natriuretic peptide, brain natriuretic peptide) and 
contribution to the diastolic filling of the left ventricle5. 
In general, the inclusion criteria for LAAC consist of: 1) 
absence of intracardiac thrombus or dense spontaneous 
echo contrast by transesophageal echocardiogram; 2) any 
adverse anatomy such as multiple LAA lobes; and 3) LAA 
ostium diameter > 17 mm and < 28 mm (32 mm for 
Watchman device) and LAA length > 20 mm; dimensions 
suitable to accommodate the prosthesis. Multilobular LAA 
and ostium geometric variability may result in an incomplete 
seal of the appendage. 
In the largest single center observational study of the 
subject by Guérios et al.6, the authors report the short- 
and mid-term results of LAAC using the Amplatzer cardiac 
plug. The study, which included 86 patients with a high 
predicted risk score of 2.6% by CHADS2, demonstrated 
high procedural success (99%) with a low rate of acute 
or subacute complications, including 2 cerebrovascular 
events. Of note, there was a high 97% rate of complete 
LAAC by echocardiogram 3 to 6 months after the procedure 
with no strokes or late device embolization. The overall 
rate of complications in this report was lower than in 
previous smaller registries as well as in the PROTECT-
AF trial or the Multicentric European Experience4,7. It is 
noteworthy that most patients in the study by Guérios 
et al7 (55.8%) underwent concomitant procedures along 
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with LAAC (e.g., transcatheter aortic valve implantation, 
percutaneous coronary intervention, patent foramen ovale 
or atrial septal defect closure) ─ that were once considered 
exclusion criteria in the PROTECT AF trial. The authors also 
report the feasibility and safety of the elegant practice of 
performing the procedure guided by angiography alone. 
Most importantly, although it is an observational study and 
there is no direct comparison with oral anticoagulation, 
no events in this cohort were observed during follow-up 
against an estimated rate of 5.2% embolic events/year by 
CHADS2 score.
The challenge of selecting patients for percutaneous 
LAAC relies on 4 main factors: 1) there is a lack of equipoise 
when comparing LAAC vs. medical therapy in patients 
with contraindications to oral anticoagulation. For ethical 
reasons, such a head-to-head comparison cannot be 
conducted. Thus, since there is no alternative option to 
prevent embolic strokes, patients who are contraindicated 
for anticoagulants seem to be the ideal candidates for LAAC; 
2) conversely, in patients eligible for oral anticoagulation, 
there is a paucity of data comparing the 2 strategies; as 
mentioned before, PROTECT AF4 is the only randomized 
trial thus far comparing LAAC vs. oral anticoagulation. 
The trial demonstrated noninferiority with regard to the 
primary endpoint, although a higher risk of procedural 
complications was shown, a finding most likely biased by 
the initial learning curve. As with all new interventional 
procedures, however, there has been a significant 
improvement in the safety of LAAC with increased operator 
experience8 and device development, a phenomenon 
previously demonstrated and corroborated by Guérios 
et al6. Further randomized controlled trials with longer 
follow-up comparing novel LAAC procedures (such as with 
the Amplatzer Cardiac Plug) with oral anticoagulation are 
required to investigate the impact of LAAC on these lower 
risk patients (i.e., patients eligible for oral anticoagulant). 
Furthermore, the role of these devices in lower risk patients 
in the era of novel anticoagulants, including the use of oral 
factor Xa inhibitors apixaban and rivaroxaban, and the direct 
thrombin inhibitor dabigatran, should also be determined in 
further randomized controlled trials. Although compliance 
may improve with these novel anticoagulants and the 
risk of bleeding complications can be somewhat reduced 
compared with warfarin, there is still an increased risk of 
bleeding over time9. Guidelines for non-pharmacological 
approaches to prevention of thromboembolism such as 
percutaneous LAAC are pending the results of additional 
ongoing trials. At present, the indication for the procedure 
must be individualized after a thorough evaluation of the 
patient’s global risk, which includes balancing the risk of 
stroke and bleeding; 3) LAAC may contribute to a reduction 
in the risk of thromboembolism, but this may result in 
undesirable physiological sequelae such as reduced atrial 
compliance and a decreased capacity for atrial natriuretic 
factor secretion in response to pressure and volume 
overload. Nonetheless, these physiological consequences 
are still unknown; and, finally 4) the cost-effectiveness of 
the procedure must be explored in future studies, weighing 
the initial substantial cost of the device against the total cost 
of long-term oral anticoagulation therapy. 
In conclusion, LAAC is an acceptable therapeutic 
option in selected high-risk patients with non-valvular AF 
who are suboptimal candidates — or not candidates at 
all — for oral anticoagulant therapy. Once deemed “our 
most lethal human attachment” in AF patients10, the LAA 
can now be safely and efficaciously excluded, isolated, 
and imprisoned percutaneously with a life sentence for 
causing embolic strokes.
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